Zydus Cadila unit launches udenafil for erectile dysfunction in India

18 July 2012

Zydus Urosciences, the specialty division of Indian drugmaker Zydus Cadila, is launching udenafil a next generation therapy for the treatment of erectile dysfunction (ED). Udenafil, a newly developed, potent and selective PDE5 inhibitor approved for the treatment of ED, is being launched under the brand name Udzire.

The group has an exclusive license to market this patented molecule developed by Dong-A Pharmaceuticals of South Korea, in India. The drug, trade named Zydema, first gained approval in Korea in 2005, with other approvals following.

Phosphodiesterase 5 (PDE5) inhibitors are the first line therapy for ED. Currently, only two molecules – sildenafil (Pfizer’s Viagra) and tadalafil (Eli Lilly’s Cialis) from this group are available for the treatment of ED in India. Sildenafil has a rapid onset of action but duration of action is shorter. Tadalafil has a longer duration of action but is associated with side effects of muscle and back pain.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK